iPrEx
Status:Completed
Phase:III
Principal Investigator(s):Robert M. Grant, MD, MPH
Objective:Determine whether daily oral TDF/FTC can reduce the risk of HIV infection in men who have sex men and transgender who also receive HIV counselling, condoms, and treatment for other STIs.Key result: 44% reduction in HIV infection rate among MSM across 11 sites in US, South America, Africa, and ThailandLast update August 9, 2022
Prevention Option(s):PrEP
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionDaily dosing
Mode of DeliveryTablet
ARMsExperimental
Official Code:
NCT00458393
Trial Sponsors:
Bill & Melinda Gates Foundation, NIAID
Start Date
End Date
June 30, 2007
February 28, 2014
Enrollment:2,499
Age range:
18 Years ↔
any
Population:Gay and Bisexual Men Who Have Sex with Men